Syndax Pharmaceuticals In... (SNDX)
NASDAQ: SNDX
· Real-Time Price · USD
15.82
0.44 (2.83%)
At close: Oct 01, 2025, 1:52 PM
2.83% (1D)
| Bid | 15.8 |
| Market Cap | 1.36B |
| Revenue (ttm) | 78.18M |
| Net Income (ttm) | -334.99M |
| EPS (ttm) | -3.82 |
| PE Ratio (ttm) | -4.14 |
| Forward PE | -8.94 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 15.82 |
| Volume | 731,144 |
| Avg. Volume (20D) | 2,238,992 |
| Open | 15.50 |
| Previous Close | 15.38 |
| Day's Range | 15.28 - 15.92 |
| 52-Week Range | 8.58 - 22.50 |
| Beta | 0.72 |
| Ex-Dividend Date | n/a |
About SNDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SNDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SNDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSyndax Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 4, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+21.1%
Syndax Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
6 months ago
+7.47%
Syndax Pharmaceuticals shares are trading higher after JP Morgan raised its price target on the stock from $39 to $41 and maintained an Overweight rating.
1 month ago · seekingalpha.com
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Met...
1 month ago · fool.com
Syndax (SNDX) Q2 Revenue Jumps 986%Syndax (SNDX) Q2 Revenue Jumps 986%